United Therapeutics (UTHR) Debt to Equity (2010 - 2025)

United Therapeutics has disclosed Debt to Equity across 14 years of filings, most recently posting $0.03 for Q1 2025.

• Debt to Equity for Q1 2025 came in at $0.03, down 73.86% year-over-year; the trailing twelve-month figure through Mar 2025 was $0.03 (down 73.86% YoY), and the FY2024 annual result was $0.05, down 60.2% from the prior year.
• Debt to Equity came in at $0.03 for Q1 2025 at United Therapeutics, down from $0.05 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.23 in Q1 2021 to a low of $0.03 in Q1 2025.
• The 5-year median for Debt to Equity is $0.16 (2023), against an average of $0.15.
• Across the five-year window, Debt to Equity decreased 14.24% in 2021 and sank 73.86% in 2025, its largest moves.
• United Therapeutics' Debt to Equity stood at $0.2 in 2021, then fell by 17.47% to $0.17 in 2022, then retreated by 29.87% to $0.12 in 2023, then sank by 60.2% to $0.05 in 2024, then plunged by 36.89% to $0.03 in 2025.
• The last three Debt to Equity figures came in at $0.03 (Q1 2025), $0.05 (Q4 2024), and $0.07 (Q3 2024), per Business Quant data.